Behind the Scenes of Eli Lilly's Latest Options Trends - Eli Lilly (NYSE:LLY)

Company Overview - Eli Lilly is a pharmaceutical company focusing on neuroscience, cardiometabolic diseases, cancer, and immunology, with key products including Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant [11]. Market Sentiment - Recent options trading indicates a bearish sentiment among large investors, with 42% bearish and 39% bullish positions noted [3]. - A total of 33 uncommon options trades were identified, with 9 puts amounting to $1,005,471 and 24 calls totaling $1,892,620 [2][3]. Options Analysis - The average open interest for Eli Lilly options is 420.12, with a total volume of 954.00, indicating significant trading activity [5]. - The price target for Eli Lilly based on recent options activity is projected between $500.0 and $1600.0 [4]. Expert Ratings - Analysts have provided an average target price of $1,222.67 for Eli Lilly, with individual ratings from Wells Fargo, BMO Capital, and B of A Securities maintaining target prices of $1,200 and $1,268 [12][13]. Current Stock Performance - Eli Lilly's stock price is currently at $1,064.19, reflecting a decrease of 0.98%, with upcoming earnings expected in 34 days [15].